Ilke Sipahi1, Sara M Debanne, Douglas Y Rowland, Daniel I Simon, James C Fang. 1. Harrington-McLaughlin Heart & Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. ilkesipahi@gmail.com
Abstract
BACKGROUND: Angiotensin-receptor blockers (ARBs) are a widely used drug class approved for treatment of hypertension, heart failure, diabetic nephropathy, and, recently, for cardiovascular risk reduction. Experimental studies implicate the renin-angiotensin system, particularly angiotensin II type-1 and type-2 receptors, in the regulation of cell proliferation, angiogenesis, and tumour progression. We assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs. METHODS: We searched Medline, Scopus (including Embase), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the US Food and Drug Administration website for studies published before November, 2009, that included any of the seven currently available ARBs. Randomised controlled trials with an ARB given in at least one group, with a follow-up of at least 1 year, and that enrolled at least 100 patients were included. New-cancer data were available for 61,590 patients from five trials. Data on common types of solid organ cancers were available for 68,402 patients from five trials, and data on cancer deaths were available for 93,515 patients from eight trials. FINDINGS: Telmisartan was the study drug in 30,014 (85.7%) patients who received ARBs as part of the trials with new cancer data. Patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2%vs 6.0%, risk ratio [RR] 1.08, 95% CI 1.01-1.15; p=0.016). When analysis was limited to trials where cancer was a prespecified endpoint, the RR was 1.11 (95% CI 1.04-1.18, p=0.001). Among specific solid organ cancers examined, only new lung-cancer occurrence was significantly higher in patients randomly assigned to receive ARBs than in those assigned to receive control (0.9%vs 0.7%, RR 1.25, 1.05-1.49; p=0.01). No statistically significant difference in cancer deaths was observed (1.8%vs 1.6%, RR 1.07, 0.97-1.18; p=0.183). INTERPRETATION: This meta-analysis of randomised controlled trials suggests that ARBs are associated with a modestly increased risk of new cancer diagnosis. Given the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each particular drug. These findings warrant further investigation. 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: Angiotensin-receptor blockers (ARBs) are a widely used drug class approved for treatment of hypertension, heart failure, diabetic nephropathy, and, recently, for cardiovascular risk reduction. Experimental studies implicate the renin-angiotensin system, particularly angiotensin II type-1 and type-2 receptors, in the regulation of cell proliferation, angiogenesis, and tumour progression. We assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs. METHODS: We searched Medline, Scopus (including Embase), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the US Food and Drug Administration website for studies published before November, 2009, that included any of the seven currently available ARBs. Randomised controlled trials with an ARB given in at least one group, with a follow-up of at least 1 year, and that enrolled at least 100 patients were included. New-cancer data were available for 61,590 patients from five trials. Data on common types of solid organ cancers were available for 68,402 patients from five trials, and data on cancer deaths were available for 93,515 patients from eight trials. FINDINGS:Telmisartan was the study drug in 30,014 (85.7%) patients who received ARBs as part of the trials with new cancer data. Patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2%vs 6.0%, risk ratio [RR] 1.08, 95% CI 1.01-1.15; p=0.016). When analysis was limited to trials where cancer was a prespecified endpoint, the RR was 1.11 (95% CI 1.04-1.18, p=0.001). Among specific solid organ cancers examined, only new lung-cancer occurrence was significantly higher in patients randomly assigned to receive ARBs than in those assigned to receive control (0.9%vs 0.7%, RR 1.25, 1.05-1.49; p=0.01). No statistically significant difference in cancer deaths was observed (1.8%vs 1.6%, RR 1.07, 0.97-1.18; p=0.183). INTERPRETATION: This meta-analysis of randomised controlled trials suggests that ARBs are associated with a modestly increased risk of new cancer diagnosis. Given the limited data, it is not possible to draw conclusions about the exact risk of cancer associated with each particular drug. These findings warrant further investigation. 2010 Elsevier Ltd. All rights reserved.
Authors: Thomas Walther; Andreas Menrad; Hans-Dieter Orzechowski; Gerhard Siemeister; Martin Paul; Michael Schirner Journal: FASEB J Date: 2003-11 Impact factor: 5.191
Authors: Nish Chaturvedi; Massimo Porta; Ronald Klein; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Anne Katrin Sjølie Journal: Lancet Date: 2008-09-25 Impact factor: 79.321
Authors: Anne Katrin Sjølie; Ronald Klein; Massimo Porta; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Nish Chaturvedi Journal: Lancet Date: 2008-09-25 Impact factor: 79.321
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Christopher B Granger; John J V McMurray; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Marc A Pfeffer; Karl Swedberg Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Benjamin J Powers; Remy R Coeytaux; Rowena J Dolor; Vic Hasselblad; Uptal D Patel; William S Yancy; Rebecca N Gray; R Julian Irvine; Amy S Kendrick; Gillian D Sanders Journal: J Gen Intern Med Date: 2011-12-07 Impact factor: 5.128
Authors: Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Beatrice Nardone; Sara Majewski; Ashley S Kim; Tina Kiguradze; Estela M Martinez-Escala; Rivka Friedland; Ahmad Amin; Anne E Laumann; Beatrice J Edwards; Alfred W Rademaker; Mary C Martini; Dennis P West Journal: Drug Saf Date: 2017-03 Impact factor: 5.606